Recursion Pharmaceuticals, Inc.
RXRX
$4.55
$0.235.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -32.98% | 30.14% | 29.32% | 32.00% | 37.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.98% | 30.14% | 29.32% | 32.00% | 37.64% |
| Cost of Revenue | 66.86% | 54.63% | 42.51% | 26.72% | 26.47% |
| Gross Profit | -91.64% | -59.09% | -44.88% | -25.74% | -23.97% |
| SG&A Expenses | 66.03% | 74.36% | 67.19% | 60.86% | 30.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.62% | 60.12% | 49.53% | 36.31% | 27.53% |
| Operating Income | -83.04% | -63.87% | -52.00% | -36.86% | -26.01% |
| Income Before Tax | -86.89% | -70.69% | -60.27% | -39.94% | -30.89% |
| Income Tax Expenses | 97.15% | 100.30% | 89.53% | 72.23% | -- |
| Earnings from Continuing Operations | -89.42% | -73.14% | -62.31% | -41.33% | -29.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -89.42% | -73.14% | -62.31% | -41.33% | -29.12% |
| EBIT | -83.04% | -63.87% | -52.00% | -36.86% | -26.01% |
| EBITDA | -77.48% | -60.65% | -50.34% | -35.91% | -24.03% |
| EPS Basic | -17.10% | -8.88% | -9.78% | -5.65% | -5.48% |
| Normalized Basic EPS | -15.02% | -6.99% | -8.13% | -4.81% | -6.76% |
| EPS Diluted | -17.27% | -9.05% | -9.95% | -5.83% | -5.48% |
| Normalized Diluted EPS | -15.02% | -6.99% | -8.13% | -4.81% | -6.76% |
| Average Basic Shares Outstanding | 62.93% | 57.12% | 44.42% | 32.07% | 24.08% |
| Average Diluted Shares Outstanding | 62.93% | 57.12% | 44.42% | 32.07% | 24.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |